# Regeneron Pharmaceuticals, Inc.  Share Price Target ‘$1,065.64’, now 4.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc.share-price-target-1065.64-now-4.1-upside-potential/4121163982
- Published: 2024-07-05T15:45:42+01:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** with ticker code (REGN) have now 24 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between $1,229.00 and
$720.00 suggesting an average analyst share price target price of $1,065.64. (at
the time of writing). Given that the stocks previous close was at $1,024.09 this
is indicating there is a potential upside of 4.1%. It’s also worth noting that there
is a 50 day moving average of $988.30 and the 200 day moving average is $911.90.
The market capitalization for the company is 113.91B. The current share price for
the company is: $1,033.84 USD

 The potential market cap would be $118,535,936,342 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 30.5, revenue per share of $122.57
and a 7.74% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on: